Counseling and Management of R&D Activities in Immunotherapy and Vaccines

Explore & Develop

New R&D Territories in

Immunotherapy & Prevention of

Cancer, Immune Disorders, and Infectious Diseases

Contact details: Rémi Palmantier, PhD, President & Founder of ImmThera Consulting SAS, France.

email: remip@immthera.com - Linkedin profile

IMMTHERA CONSULTING

HELPS YOU TO BUILD ON THE COMPLEX

SCIENTIFIC AND R&D EQUATION

OF IMMUNOTHERAPY SUCCESSES & FUTURE PROMISES

The time has come to a new wave of immune-based innovative products

for the treatment of cancer and chronic disorders

-----------------------------------------------------------

A turning point in cancer treatment in 2011 with the first FDA approved immune checkpoint inhibitor and followers (ie. anti-PD(L)-1, BiTEs & CAR-T cells) in multiple indications

+

The successful achievements of multiple biologics & drugs targeting immune regulation to better control chronic autoimmune/allergic/inflammatory diseases

+

An outstanding history of success of the prophylactic vaccines and the advent of modern vaccinology

+

An extensive know-how & lessons learned from the many unproductive attempts to develop therapeutic immunization

(cancer, autoimmunity/allergy, virus)

+

A much deeper understanding of cellular and molecular immunology, pathophysiology, and homeostasis (innate & adaptive immunity, immune tolerance, Immune Checkpoint Blockade, biomarkers, tumor neoantigens, disease-related antigens...)

+

The continual innovation and improvement of technologies to boost, regulate, and monitor the immunity

(eg. delivery platforms, immunomodulators, translational research)

+

Accessibility to a broader choice of preclinical models and key technologies, eg. humanized mice, organoids, targeting, Big data, WES, NGS, single cell analysis, gene editing …

+

A changing environment, ie. regulatory constraints & opportunities, multiplication of CROs...

=

The advent of immuno-oncology as a specific, measurable, actionable, and realistic tool for treatment

A surge of new biologics & targeted therapies getting closer to the root-cause of the auto-immune and allergic processes

A broad variety of highly promising and risky new projects, targets & technical opportunities based on immune-mediated MoA

IMMTHERA SOLUTIONS

> MAKE THE LINKS & HELP TO FIND THE RIGHT PATH

> DEVELOP THE RIGHT PROJECT THE RIGHT WAY

> BUILD R&D STRATEGY PLAN

> IMPLEMENT & MANAGE PROJECTS FROM DISCOVERY TO CLINICAL DEVELOPMENT STAGE

Contacts :Rémi Palmantier, PhDPresident & Founder of ImmThera Consulting SAS, Franceemail: remip@immthera.comLinkedin profile